Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations

H.E. Jo, Sarvin Randhawa, T.J. Corte, Yuben Moodley

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

© 2016 Springer International Publishing Switzerland Idiopathic pulmonary fibrosis (IPF) is a severe and progressive fibrosing interstitial lung disease, which ultimately results in respiratory failure and death. The median age at diagnosis is 66 years, and the incidence increases with age, making this a disease that predominantly affects the elderly population. IPF can often be difficult to diagnose, as its symptoms—cough, dyspnoea and fatigue—are non-specific and can often be attributed to co-morbidities such as heart failure and chronic obstructive pulmonary disease. Making an accurate diagnosis of IPF is imperative, as new treatments that appear to slow the progression of IPF have recently become available. Pirfenidone and nintedanib are two such treatments, which have shown efficacy in randomised controlled trials. As with all new treatments, caution must be advocated in the elderly, as these patients often lie outside the narrow clinical trial cohorts that are studied, and the benefits of therapy must be weighed against potential toxicities. Both medications, while relatively safe, have been associated with adverse effects, particularly gastrointestinal symptoms such as nausea, diarrhoea and anorexia. In this review, we highlight measures to improve recognition and accurate diagnosis of IPF, as well as co-morbidities that often affect the diagnosis and disease course. The gold standard for IPF diagnosis is a multidisciplinary meeting whereby clinicians, radiologists and histopathologists reach a consensus after interactive discussion. In many cases, a lung biopsy may not be available because of high risk or patient choice, particularly in the elderly. In these cases, there is debate as to whether a biopsy is required, given the high rates of IPF in patients over the age of 70 years with interstitial changes on computed tomography. We also discuss the management of IPF, drawing particular attention to specific issues affecting the elderly population, especially with regard to polypharmacy and end-of-life care. Through this article, we endeavour to improve awareness of this devastating disease and thus improve recognition of the disease and its outcomes in elderly patients.
Original languageEnglish
Pages (from-to)1-14
JournalDrugs and Aging
Volume33
Issue number5
DOIs
Publication statusPublished - 2016

Fingerprint

Idiopathic Pulmonary Fibrosis
Morbidity
Biopsy
Polypharmacy
Terminal Care
Interstitial Lung Diseases
Anorexia
Therapeutics
Switzerland
Respiratory Insufficiency
Dyspnea
Chronic Obstructive Pulmonary Disease
Nausea
Population
Diarrhea
Randomized Controlled Trials
Heart Failure
Tomography
Clinical Trials
Lung

Cite this

Jo, H.E. ; Randhawa, Sarvin ; Corte, T.J. ; Moodley, Yuben. / Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. In: Drugs and Aging. 2016 ; Vol. 33, No. 5. pp. 1-14.
@article{7532f50f711e411f85f9f67a0a902279,
title = "Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations",
abstract = "{\circledC} 2016 Springer International Publishing Switzerland Idiopathic pulmonary fibrosis (IPF) is a severe and progressive fibrosing interstitial lung disease, which ultimately results in respiratory failure and death. The median age at diagnosis is 66 years, and the incidence increases with age, making this a disease that predominantly affects the elderly population. IPF can often be difficult to diagnose, as its symptoms—cough, dyspnoea and fatigue—are non-specific and can often be attributed to co-morbidities such as heart failure and chronic obstructive pulmonary disease. Making an accurate diagnosis of IPF is imperative, as new treatments that appear to slow the progression of IPF have recently become available. Pirfenidone and nintedanib are two such treatments, which have shown efficacy in randomised controlled trials. As with all new treatments, caution must be advocated in the elderly, as these patients often lie outside the narrow clinical trial cohorts that are studied, and the benefits of therapy must be weighed against potential toxicities. Both medications, while relatively safe, have been associated with adverse effects, particularly gastrointestinal symptoms such as nausea, diarrhoea and anorexia. In this review, we highlight measures to improve recognition and accurate diagnosis of IPF, as well as co-morbidities that often affect the diagnosis and disease course. The gold standard for IPF diagnosis is a multidisciplinary meeting whereby clinicians, radiologists and histopathologists reach a consensus after interactive discussion. In many cases, a lung biopsy may not be available because of high risk or patient choice, particularly in the elderly. In these cases, there is debate as to whether a biopsy is required, given the high rates of IPF in patients over the age of 70 years with interstitial changes on computed tomography. We also discuss the management of IPF, drawing particular attention to specific issues affecting the elderly population, especially with regard to polypharmacy and end-of-life care. Through this article, we endeavour to improve awareness of this devastating disease and thus improve recognition of the disease and its outcomes in elderly patients.",
author = "H.E. Jo and Sarvin Randhawa and T.J. Corte and Yuben Moodley",
year = "2016",
doi = "10.1007/s40266-016-0366-1",
language = "English",
volume = "33",
pages = "1--14",
journal = "Drugs & Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "5",

}

Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. / Jo, H.E.; Randhawa, Sarvin; Corte, T.J.; Moodley, Yuben.

In: Drugs and Aging, Vol. 33, No. 5, 2016, p. 1-14.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations

AU - Jo, H.E.

AU - Randhawa, Sarvin

AU - Corte, T.J.

AU - Moodley, Yuben

PY - 2016

Y1 - 2016

N2 - © 2016 Springer International Publishing Switzerland Idiopathic pulmonary fibrosis (IPF) is a severe and progressive fibrosing interstitial lung disease, which ultimately results in respiratory failure and death. The median age at diagnosis is 66 years, and the incidence increases with age, making this a disease that predominantly affects the elderly population. IPF can often be difficult to diagnose, as its symptoms—cough, dyspnoea and fatigue—are non-specific and can often be attributed to co-morbidities such as heart failure and chronic obstructive pulmonary disease. Making an accurate diagnosis of IPF is imperative, as new treatments that appear to slow the progression of IPF have recently become available. Pirfenidone and nintedanib are two such treatments, which have shown efficacy in randomised controlled trials. As with all new treatments, caution must be advocated in the elderly, as these patients often lie outside the narrow clinical trial cohorts that are studied, and the benefits of therapy must be weighed against potential toxicities. Both medications, while relatively safe, have been associated with adverse effects, particularly gastrointestinal symptoms such as nausea, diarrhoea and anorexia. In this review, we highlight measures to improve recognition and accurate diagnosis of IPF, as well as co-morbidities that often affect the diagnosis and disease course. The gold standard for IPF diagnosis is a multidisciplinary meeting whereby clinicians, radiologists and histopathologists reach a consensus after interactive discussion. In many cases, a lung biopsy may not be available because of high risk or patient choice, particularly in the elderly. In these cases, there is debate as to whether a biopsy is required, given the high rates of IPF in patients over the age of 70 years with interstitial changes on computed tomography. We also discuss the management of IPF, drawing particular attention to specific issues affecting the elderly population, especially with regard to polypharmacy and end-of-life care. Through this article, we endeavour to improve awareness of this devastating disease and thus improve recognition of the disease and its outcomes in elderly patients.

AB - © 2016 Springer International Publishing Switzerland Idiopathic pulmonary fibrosis (IPF) is a severe and progressive fibrosing interstitial lung disease, which ultimately results in respiratory failure and death. The median age at diagnosis is 66 years, and the incidence increases with age, making this a disease that predominantly affects the elderly population. IPF can often be difficult to diagnose, as its symptoms—cough, dyspnoea and fatigue—are non-specific and can often be attributed to co-morbidities such as heart failure and chronic obstructive pulmonary disease. Making an accurate diagnosis of IPF is imperative, as new treatments that appear to slow the progression of IPF have recently become available. Pirfenidone and nintedanib are two such treatments, which have shown efficacy in randomised controlled trials. As with all new treatments, caution must be advocated in the elderly, as these patients often lie outside the narrow clinical trial cohorts that are studied, and the benefits of therapy must be weighed against potential toxicities. Both medications, while relatively safe, have been associated with adverse effects, particularly gastrointestinal symptoms such as nausea, diarrhoea and anorexia. In this review, we highlight measures to improve recognition and accurate diagnosis of IPF, as well as co-morbidities that often affect the diagnosis and disease course. The gold standard for IPF diagnosis is a multidisciplinary meeting whereby clinicians, radiologists and histopathologists reach a consensus after interactive discussion. In many cases, a lung biopsy may not be available because of high risk or patient choice, particularly in the elderly. In these cases, there is debate as to whether a biopsy is required, given the high rates of IPF in patients over the age of 70 years with interstitial changes on computed tomography. We also discuss the management of IPF, drawing particular attention to specific issues affecting the elderly population, especially with regard to polypharmacy and end-of-life care. Through this article, we endeavour to improve awareness of this devastating disease and thus improve recognition of the disease and its outcomes in elderly patients.

U2 - 10.1007/s40266-016-0366-1

DO - 10.1007/s40266-016-0366-1

M3 - Article

VL - 33

SP - 1

EP - 14

JO - Drugs & Aging

JF - Drugs & Aging

SN - 1170-229X

IS - 5

ER -